A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients with Advanced or Refractory Solid Tumours
Latest Information Update: 12 Nov 2024
At a glance
- Drugs OMO-2 (Primary)
- Indications Lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors DeuterOncology
Most Recent Events
- 07 Nov 2024 Planned End Date changed from 1 Apr 2025 to 1 Dec 2026.
- 07 Nov 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Dec 2025.
- 25 Oct 2024 Results (n=10) assessing the preliminary findings from a first-in-human phase I trial of DO-2 in patients with advanced solid tumors harboring MET aberrations, aiming to determine safety and the recommended phase 2 dose (RP2D) were presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.